Supplement Guide | Probiotics 02 | Before You Take a Probiotic, Read the Science

This is Part 2 of SuppCo's 4-part series on probiotics. We'll cover the biology of your gut microbiome, what probiotics actually are, and how the full family of "biotics" fits together.

To read part 1 in the series, click here.

Before we begin, a note… Probiotic strains often have long, complex names. Many of those names are mentioned in this article. Take your time reading the studies and (as always) if you have specific questions, ask them in the comments section.

The probiotic market generates more than $50 billion annually. The research base behind it is enormous, sprawling across thousands of clinical trials. And yet the most important thing the science tells us is also the thing that gets lost most often in the marketing.

Not all probiotics are the same. The evidence for one strain does not transfer to another strain. And the conditions where probiotics have the strongest evidence are much narrower than most product labels imply.

Saying "probiotics are good for gut health" is like saying "medication is good for your health."

This article is about specificity. We'll cover the conditions with the strongest clinical evidence, name the strains that have earned it, cite the studies, and be clear about where the data is thin or contested. The goal is to give you a research framework you can actually use the next time you're evaluating a product or deciding whether a probiotic makes sense for a given goal.

The Strongest Case: Antibiotic-Associated Diarrhea

Antibiotic-associated diarrhea, or AAD, is the most evidence-rich indication in probiotic research. When you take a broad-spectrum antibiotic, it disrupts your gut microbiome broadly, sometimes severely. AAD affects roughly 5 to 35% of people taking antibiotics depending on the drug class and individual factors. It ranges from mild loose stools to, in serious cases, bloody diarrhea caused by Clostridioides difficile infection.

The strain with the deepest evidence base here is Lactobacillus rhamnosus GG, typically abbreviated as LGG. In a meta-analysis of 12 randomized controlled trials involving 1,499 participants, LGG reduced the risk of AAD from 22.4% in placebo groups down to 12.3% in the treatment groups, a relative risk reduction of roughly 49%. That number is clinically meaningful. Due to significant differences between the included trials, the quality of evidence was rated moderate to low, which is worth flagging, but the directional consistency across trials is notable.

A second strain with strong AAD evidence is Saccharomyces boulardii CNCM I-745, often shortened to S. boulardii. Unlike LGG, which is a bacterium, S. boulardii is a yeast, and it behaves differently in the gut. Because it is not a bacterium, antibiotics do not kill it. This makes it uniquely useful in the context of concurrent antibiotic use.

Here is how the two leading AAD strains compare in practical terms:

• LGG: The most studied probiotic strain in the world, with over than 200 clinical trials behind it. For AAD specifically, start it concurrent with your antibiotic course and continue for at least one week after finishing. The dose range used in clinical trials runs from 10 to 20 billion CFU daily.

• S. boulardii: A yeast, not a bacterium, which means antibiotics cannot kill it. This makes it uniquely suited for concurrent antibiotic use. Evidence extends to C. difficile prevention specifically, and it can be taken alongside LGG rather than instead of it.

IBS: Promising, But Read the Fine Print

Irritable bowel syndrome is the second major area of probiotic research, and it is more complicated. IBS is a functional disorder with multiple subtypes (IBS-D for diarrhea-predominant, IBS-C for constipation-predominant, IBS-M for mixed), and the probiotic evidence varies by subtype, strain, and symptom outcome.

A 2023 meta-analysis reviewed 82 randomized controlled trials involving more than 10,000 IBS patients. For global IBS symptoms, there was moderate-certainty evidence for a benefit from Escherichia strains, low-certainty evidence for Lactobacillus strains and Lactiplantibacillus plantarum 299v, and very low certainty for most combination probiotics. That is a more modest finding than the supplement industry tends to communicate.

For IBS, probiotics show real benefit for some patients with some strains, the evidence is strongest for symptom relief, and treatment duration of at least 8 weeks appears necessary to see consistent effects.

Immune Function: A Real Signal, With Caveats

The gut houses roughly 70% of your immune tissue. The connection between gut microbiome health and immune function is biologically well-established. What is more variable is whether taking a specific probiotic strain produces a measurable immune outcome.

The strongest evidence here is in two populations: children in childcare settings and older adults, where immune defense is either still developing or declining with age. A systematic review of eight randomized controlled trials in adults over 60 found that certain probiotic strains, including Lacticaseibacillus rhamnosus GG (LGG) and Lacticaseibacillus paracasei CNCM I-1518 (L. paracasei), outperformed placebo in reducing the incidence of upper respiratory tract infections, though not all strains or studies reached statistical significance.

A 2025 trial published studied 128 children with upper respiratory infections. A combination of Bifidobacterium breve M-16V, Bifidobacterium lactis HN019, and Lactobacillus rhamnosus HN001 shortened fever duration by 2 days compared to placebo, a statistically significant difference.

For healthy adults without immune compromise or a specific clinical context, the evidence is thinner. Some trials show modest reductions in cold duration or severity. Many show no significant effect. The signal does exist, but the effect size in healthy populations is small. If immune support is the goal, the evidence is stronger for consistent use over time than for short-term supplementation ahead of a specific event.

The Gut-Brain Connection: Real Biology, Early Evidence

The gut-brain axis is one of the most active areas in microbiome research right now. We introduced it in Part 1 as a bidirectional communication network connecting the enteric and central nervous systems. The clinical question is whether targeting the gut microbiome with specific probiotic strains can produce measurable changes in mood, stress, anxiety, or cognitive function. These strains are sometimes called psychobiotics.

A 2024 systematic review of 51 randomized clinical trials involving 3,353 patients found notably high effectiveness of psychobiotics specifically for depression symptoms, with most trials using Lactobacillus and Bifidobacterium strains over 4 to 24 weeks. The mechanism appears to involve probiotic influence on neurotransmitter precursors, including serotonin and GABA, as well as reductions in systemic inflammation.

Despite general agreement on effectiveness in the published literature, variability in treatment approaches and clinical presentations limits how far the findings can be generalized. Most trials are small. Strain selection is inconsistent across studies. And healthy populations with low baseline stress show smaller effects than populations with diagnosed depression or anxiety disorders.

The gut-brain axis is indeed real, the mechanistic plausibility is strong, and early clinical evidence is encouraging. But this field is not yet at the stage where a specific strain can be prescribed for a specific mood outcome with confidence. We will return to the specific frontier of psychobiotics in Part 3.

The gut-brain axis runs in both directions. What you do for your gut can affect your brain.

Where the Evidence Is... Less convincing.

Not every probiotic claim holds up under scrutiny. Three areas deserve particular skepticism.

Weight management. The marketing of probiotics for weight loss has significantly outpaced the science. While gut microbiome composition is associated with metabolic outcomes in observational data, and some animal studies show compelling effects, the human RCT evidence for probiotic-driven weight loss is inconsistent and the effect sizes, where they exist, are small. Gut health as a foundation for metabolic health is a reasonable framework. Probiotics as a weight loss tool is not.

Skin conditions. The gut-skin axis is an emerging area of research, and there is early evidence for probiotics in eczema and acne. A 2025 meta-analysis of four RCTs found that probiotic supplementation reduced acne severity scores and non-inflammatory lesion counts compared to controls, though a trend toward improvement in inflammatory lesions did not reach statistical significance, and heterogeneity across studies was moderate to high. This is interesting but not definitive. Strain selection, dosing, and study duration varied too widely across trials to draw firm conclusions.

UTI prevention. Some Lactobacillus strains have been studied for urinary tract infection prevention in women, particularly Lactobacillus rhamnosus GR-1 (L. rhamnosus GR-1) and Lactobacillus reuteri RC-14 (L. reuteri RC-14). The biological rationale makes sense: vaginal Lactobacillus dominance is associated with lower UTI risk. The clinical evidence is suggestive, but not yet robust enough for confident recommendation. A 2021 meta-analysis found no significant reduction in UTI recurrence compared to placebo, with high heterogeneity across studies reflecting variation in strains, populations, and study design.

Safety and Who Should Be Cautious

For most healthy adults, probiotics have an excellent safety profile. The 2023 meta-analysis covering more than 7,000 IBS patients found no significant increase in adverse events with probiotic use compared to placebo. Mild GI symptoms like bloating, gas, and loose stools are the most common side effects in the first few days of starting a new probiotic and typically resolve within a week.

Three groups warrant additional caution:

• Immunocompromised individuals. There are documented, though rare, cases of probiotic bacteremia and fungemia in severely immunocompromised patients. Anyone with a compromised immune system, active chemotherapy, or post-organ transplant should consult a physician before taking probiotics.

• Critically ill patients. The evidence here is mixed, and some trials in ICU settings have shown adverse outcomes with certain strains. Probiotics are not for acute critical illness.

• Individuals with central venous catheters. S. boulardii, being an airborne yeast, carries a small risk of catheter contamination in hospital settings. Relevant for healthcare workers handling the product as much as for patients.

For the general healthy population, the risk profile is very low. The more common problem is not harm from probiotics, it is spending money on a product with no clinical evidence for your stated goal.

What's Coming in Part 3

The evidence tells you which strains work. But knowing which strain you need is only half the problem. The other half is knowing whether the product you are holding actually contains what it says it does, in the form that survives long enough to matter. Part 3 covers CFU vs AFU counts, what those numbers actually mean, how survivability and storage affect what reaches your gut, and the emerging frontiers in probiotic science, including psychobiotics, gerobiotics, and the estrobolome.